Brimonidine Tartrate Patent Expiration

Brimonidine Tartrate was first introduced by Allergan Inc in its drug Alphagan on Sep 6, 1996. Other drugs containing Brimonidine Tartrate are Lumify, Mirvaso, Alphagan P, Lumify Preservative Free, Qoliana. 16 different companies have introduced drugs containing Brimonidine Tartrate.


Brimonidine Tartrate Patents

Given below is the list of patents protecting Brimonidine Tartrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Alphagan P US10307368 Compositions containing alpha-2-adrenergic agonist components Jul 10, 2021

(Expired)

Abbvie
Alphagan P US5424078

(Pediatric)

Aqueous ophthalmic formulations and methods for preserving same Dec 13, 2012

(Expired)

Abbvie
Alphagan P US6562873 Compositions containing therapeutically active components having enhanced solubility Jul 10, 2021

(Expired)

Abbvie
Alphagan P US6562873

(Pediatric)

Compositions containing therapeutically active components having enhanced solubility Jan 10, 2022

(Expired)

Abbvie
Alphagan P US6627210 Compositions containing α-2-adrenergic agonist components Jul 18, 2021

(Expired)

Abbvie
Alphagan P US6627210

(Pediatric)

Compositions containing α-2-adrenergic agonist components Jan 18, 2022

(Expired)

Abbvie
Alphagan P US6641834 Compositions containing alpha-2-adrenergic agonist components Jul 28, 2021

(Expired)

Abbvie
Alphagan P US6641834

(Pediatric)

Compositions containing alpha-2-adrenergic agonist components Jan 28, 2022

(Expired)

Abbvie
Alphagan P US6673337 Compositions containing alpha-2-adrenergic agonist components Jul 26, 2021

(Expired)

Abbvie
Alphagan P US6673337

(Pediatric)

Compositions containing alpha-2-adrenergic agonist components Jan 26, 2022

(Expired)

Abbvie
Alphagan P US8858961 Compositions containing alpha-2-adrenergic agonist components Sep 02, 2023

(Expired)

Abbvie
Alphagan P US8858961

(Pediatric)

Compositions containing alpha-2-adrenergic agonist components Mar 02, 2024

(Expired)

Abbvie
Alphagan P US9295641 Compositions containing alpha-2-adrenergic agonist components Jul 10, 2021

(Expired)

Abbvie
Alphagan P US9295641

(Pediatric)

Compositions containing alpha-2-adrenergic agonist components Jan 10, 2022

(Expired)

Abbvie
Alphagan P US9687443 Compositions containing alpha-2-adrenergic agonist components Jul 10, 2021

(Expired)

Abbvie
Alphagan P US9687443

(Pediatric)

Compositions containing alpha-2-adrenergic agonist components Jan 10, 2022

(Expired)

Abbvie
Lumify US11596600 Vasoconstriction compositions and methods of use Jul 27, 2029 Bausch And Lomb Inc
Lumify US11833245 Vasoconstriction compositions and methods of use Jul 27, 2029 Bausch And Lomb Inc
Lumify US8293742 Preferential vasoconstriction compositions and methods of use Jul 14, 2030 Bausch And Lomb Inc
Lumify US9259425 Compositions and methods for eye whitening Jul 14, 2030 Bausch And Lomb Inc
Mirvaso US10201517 Brimonidine gel compositions and methods of use Jun 13, 2031 Galderma Labs Lp
Mirvaso US7439241 Compounds, formulations, and methods for treating or preventing rosacea Aug 25, 2025 Galderma Labs Lp
Mirvaso US8053427 Brimonidine gel composition Jun 13, 2031 Galderma Labs Lp
Mirvaso US8163725 Gel compositions and methods of use Jun 13, 2031 Galderma Labs Lp
Mirvaso US8231885 Compounds, formulations, and methods for ameliorating telangiectasis May 24, 2025 Galderma Labs Lp
Mirvaso US8410102 Methods and compositions for treating or preventing erythema May 24, 2025 Galderma Labs Lp
Mirvaso US8426410 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May 24, 2025 Galderma Labs Lp
Mirvaso US8513247 Methods and compositions for safe and effective treatment of erythema Mar 25, 2031 Galderma Labs Lp
Mirvaso US8513249 Methods and compositions for safe and effective treatment of erythema Mar 25, 2031 Galderma Labs Lp
Mirvaso US8859551 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May 25, 2024

(Expired)

Galderma Labs Lp
Mirvaso US9861631 Methods and compositions for safe and effective treatment of erythema Mar 25, 2031 Galderma Labs Lp
Mirvaso US9861632 Methods and compositions for safe and effective treatment of erythema Mar 25, 2031 Galderma Labs Lp
Qoliana US7265117 Topical brimonidine tartrate formulations that lack chlorine dioxide Aug 19, 2025 Sandoz


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Brimonidine Tartrate Generics

Several generic applications have been filed for Brimonidine Tartrate. The first generic version for Brimonidine Tartrate was by Bausch And Lomb Pharmaceuticals Inc and was approved on May 28, 2003. And the latest generic version is by Upsher Smith Laboratories Llc and was approved on Jun 12, 2024.

Given below is the list of companies who have filed for Brimonidine Tartrate generic.


1. SOMERSET THERAPS LLC

Somerset Therapeutics Llc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Prescription OPHTHALMIC AT Mar 11, 2019


2. APOTEX

Apotex Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.15% solution/drops Prescription OPHTHALMIC AT Jan 31, 2022
0.1% solution/drops Prescription OPHTHALMIC AB Dec 21, 2022


3. MICRO LABS

Micro Labs Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Micro Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Prescription OPHTHALMIC AT Nov 22, 2023


4. INDOCO

Indoco Remedies Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Indoco.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Prescription OPHTHALMIC AT Nov 18, 2014


5. DR REDDYS LABS SA

Dr Reddys Laboratories Sa has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.025% solution/drops Over the counter OPHTHALMIC N/A Feb 16, 2024


6. PADAGIS ISRAEL

Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Padagis Israel.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.33% BASE gel Prescription TOPICAL AB Sep 23, 2021


7. RISING

Rising Pharma Holdings Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Rising.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Prescription OPHTHALMIC AT Mar 14, 2006


8. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.15% solution/drops Prescription OPHTHALMIC AT Mar 29, 2023
0.1% solution/drops Prescription OPHTHALMIC AB Aug 1, 2023


9. BAUSCH AND LOMB

Bausch And Lomb Pharmaceuticals Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Bausch And Lomb.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2%

(reference standard)

solution/drops Prescription OPHTHALMIC AT May 28, 2003


10. SANDOZ

Sandoz Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Prescription OPHTHALMIC AT Jan 30, 2008
0.1% solution/drops Prescription OPHTHALMIC AB Mar 4, 2024


11. TEVA PARENTERAL

Teva Parenteral Medicines Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Teva Parenteral.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2% solution/drops Discontinued OPHTHALMIC N/A Sep 10, 2004


12. UPSHER SMITH LABS

Upsher Smith Laboratories Llc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Upsher Smith Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.15% solution/drops Prescription OPHTHALMIC AT Jun 12, 2024